4 KaloBios Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $KBIO | NASDAQ:KBIO | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact KaloBios Pharmaceuticals Company Profile (NASDAQ:KBIO) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for KaloBios Pharmaceuticals (NASDAQ:KBIO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)Consensus Rating:Buy (Score: 2.50)Consensus Price Target: $7.50 (123.21% upside) Analysts' Ratings History for KaloBios Pharmaceuticals (NASDAQ:KBIO) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/27/2014JMP SecuritiesInitiated CoverageOutperform$8.00View 1/30/2014Needham & CompanyDowngradeBuy -> HoldView 1/30/2014Leerink SwannLower Price Target$15.00 -> $7.00View 3/5/2013Needham & CompanyInitiated CoverageBuy$11.00View 2/26/2013Leerink SwannInitiated CoverageOutperform$15.00View 2/26/2013William BlairInitiated CoverageOutperformView (Data available from 3/11/2012 forward) Earnings History for KaloBios Pharmaceuticals (NASDAQ:KBIO)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare11/12/2013Q3 13$0.00($0.47)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for KaloBios Pharmaceuticals (NASDAQ:KBIO)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for KaloBios Pharmaceuticals (NASDAQ:KBIO)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare1/31/20135Am Partners LlcMajor ShareholderBuy62,500$8.00$500,000.00View 1/31/2013James HealyDirectorBuy375,000$8.00$3,000,000.00View (Data available from 1/1/2013 forward) About KaloBios Pharmaceuticals KaloBios Pharmaceuticals, Inc., is a United States-based company, which develops protein therapeutics. The Company develops and engineers antibodies and protein therapeutics. Its monoclonal antibodies (mAbs) technology that is being used for reengineering antibodies with products being developed in the areas of infectious disease, autoimmunity, and oncology. Its suite of technologies can also be used for discovery and engineering of other proteins, industrial enzymes and small molecule drugs. It conducts three clinical development programs in leukemia, infectious diseases, and autoimmune diseases. Headlines: (3/10) KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences (2/11) KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies (2/20) The Wall Street Transcript Interview with David Pritchard, the President and CEO of KaloBios Pharmaceuticals, Inc ... (2/28) RDInvesting Provides Investors with Free In-Depth Equity Reports on GMED, KBIO, TIBX and VCRA Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: KBIO CUSIP: 48344T10 Key Metrics: Previous Close: $3.3650 Day Moving Average: $3.5138200 Day Moving Average: $4.3088 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $110.6MCurrent Quarter EPS Consensus Estimate: $-1.87 EPS Additional Links: View KBIO on Google FinanceView KBIO on Yahoo FinanceView KBIO's Company Profile on ReutersSearch for KaloBios Pharmaceuticals Inc. on Google KaloBios Pharmaceuticals (NASDAQ:KBIO) Chart for Tuesday, March, 11, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.